Acceleron to host an investor and analyst webcast and conference call following the virtual ATS 2020 presentation on June 24th In January, Acceleron reported that the PULSAR Phase 2 trial in patients ...
(Reuters) -Merck & Co said on Thursday it would buy Acceleron Pharma Inc for about $11.5 billion, broadening its portfolio beyond aging cancer drug Keytruda with potential treatments that could bring ...
Merck started its Acceleron pursuit at $160 per share, but CEO Davis balked at paying more than $180
Merck's new CEO Robert Davis has big shoes to fill after taking the reins from Kenneth Frazier at the start of July. Just two weeks into his tenure, though, his company was already in talks for its ...
Even though Acceleron sold itself to Merck for $180 per share last month, the company evaluated other options before pulling the trigger. One of those options was seeing whether Bristol Myers Squibb ...
Preclinical research of murine version of sotatercept reveals significant role of key TGF-beta superfamily proteins, including activin and growth differentiation factor ligands, in pulmonary vascular ...
Merck will spend about $11.5 billion to buy Acceleron Pharma and its potential treatment for high blood pressure in vessels that connect the lungs and heart. Merck will pay $180 per share in cash for ...
Merck said Sept. 30 it will acquire Acceleron Pharma for about $11.5 billion to expand its rare disease drug portfolio. Merck will pay Acceleron $180 per share in cash. Acceleron develops drugs to ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics ...
Merck will get promising pulmonary arterial hypertension drug sotatercept with its acquisition of Acceleron. Acceleron already has one drug on the market that's licensed to Bristol Myers Squibb. An ...
Sept 30 (Reuters) - Merck & Co (MRK.N), opens new tab said on Thursday it would buy Acceleron Pharma Inc (XLRN.O), opens new tab for about $11.5 billion, broadening its portfolio beyond aging cancer ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq: XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics ...
Merck & Co. said Thursday it would buy Acceleron Pharma Inc. for about $11.5 billion, broadening its portfolio beyond aging cancer drug Keytruda with potential treatments that could bring in fresh ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results